Vertex and Moderna pursue mRNA for CF | Chemical & Engineering News
Volume 94 Issue 28 | p. 15 | Concentrates
Issue Date: July 11, 2016

Vertex and Moderna pursue mRNA for CF

Department: Business
Keywords: drug discovery, mRNA, cystic fibrosis, biotechnology

Vertex Pharmaceuticals and Moderna Therapeutics are joining to research Moderna’s mRNA technology for the treatment of cystic fibrosis. Vertex, which markets two CF medicines, will pay Moderna $20 million in cash and invest an equal amount in the biotech firm. Vertex could pay future milestones of up to $275 million. Moderna struck a $200 million mRNA vaccine deal with Merck & Co. late last month. It raised $450 million from investors last year.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment